Investigational drug · Phase 3
bypassing agents
Also called: Clotting factor concentrates, CFC, BPA
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hemophilia, Von Willebrand Disease, Type 3.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
13
Any phase or sponsor naming "bypassing agents"
First trial start
2023
Feb 1, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "bypassing agents", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hemophilia
- Von Willebrand Disease, Type 3
Approved drugs for the same conditions: Hemophilia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "bypassing agents" as an intervention, largest first.
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02476942 · 221 participants · Start May 26, 2015 · Primary completion Mar 31, 2017
Drug: Bypassing Agents; FVIII Replacement · For: Hemophilia A
Sites: Santa Monica, California; Aurora, Colorado; Washington D.C., District of Columbia · 35 sites in all
- Research Study to Look at How Well the Drug Concizumab Works in Your Body if You Have Haemophilia With InhibitorsPivotal-lookingActive, not recruiting
Novo Nordisk A/SNovo Nordisk (NVO)
NCT04083781 · 134 participants · Start Oct 21, 2019 · Primary completion Dec 27, 2021
Drug: Concizumab · For: Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Sites: Orange, California; Atlanta, Georgia; Indianapolis, Indiana · 99 sites in all
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants With InhibitorsPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02622321 · 113 participants · Start Nov 18, 2015 · Primary completion Oct 25, 2016
Drug: Emicizumab; rFVIIa and 1 more · For: Hemophilia A
Sites: Los Angeles, California; Santa Monica, California; Aurora, Colorado · 44 sites in all
- A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe HemophiliaPivotal-lookingActive, not recruiting
SanofiSanofi (SNY)
NCT05662319 · 91 participants · Start Feb 1, 2023 · Primary completion Mar 25, 2027
Drug: Fitusiran; Clotting factor concentrates (CFC) or bypassing agents (BPA) and 1 more · For: Hemophilia
Sites: Orange, California; Minneapolis, Minnesota; Hackensack, New Jersey · 50 sites in all
- A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or BPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT07285460 · 85 participants (planned) · Start Dec 18, 2025 · Primary completion Aug 4, 2029
Drug: Fitusiran; Clotting factor concentrates (CFC) or bypassing agents (BPA) and 1 more · For: Hemophilia
Sites: Los Angeles, California; Orange, California; Torrance, California · 37 sites in all
- A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseasePivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06998524 · 75 participants (planned) · Start Jun 27, 2025 · Primary completion Oct 6, 2027
Drug: Emicizumab; von Willebrand Factor (VWF) Concentrates and 3 more · For: Von Willebrand Disease, Type 3
Sites: Sacramento, California; Gainesville, Florida; Lexington, Kentucky · 30 sites in all
- A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With InhibitorsPivotal-lookingCompleted
Genzyme, a Sanofi CompanySanofi (SNY)
NCT03417102 · 60 participants · Start Feb 14, 2018 · Primary completion Nov 25, 2020
Drug: fitusiran; Bypassing agents · For: Hemophilia A; Hemophilia B
Sites: Phoenix, Arizona; Los Angeles, California; Orange, California · 58 sites in all
Novo Nordisk A/SNovo Nordisk (NVO)
NCT00710619 · 52 participants · Start Jun 2008 · Primary completion Jul 2009
Drug: activated recombinant human factor VII; Feiba VH · For: Congenital Bleeding Disorder; Haemophilia A With Inhibitors; Haemophilia B With Inhibitors
Sites: Plainsboro, New Jersey
- Emicizumab in Patients With Acquired Hemophilia AActive, not recruiting
University of WashingtonAcademic, hospital or other
NCT05345197 · 51 participants (planned) · Start Aug 31, 2022 · Primary completion Jul 2026
Drug: emicizumab · For: Acquired Hemophilia A
Sites: San Diego, California; Washington D.C., District of Columbia; Atlanta, Georgia · 16 sites in all
- Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and ChildrenPivotal-lookingRecruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT07838194 · 50 participants (planned) · Start Nov 30, 2026 · Primary completion Sep 30, 2028
Drug: NXT007 · For: Hemophilia A
Sites: Kawasaki-Shi, Japan
Newest research
PubMed records naming it or its code names, newest first.
- Automated enzymatic hydrolysis-magnetic-bead-assisted sequential extraction workflow for LC-MS/MS profiling of urinary aldosterone-pathway steroids.
Li B, Liu Z, Liu P, et al. · Talanta 2027
- Visible light-driven sustainable peroxymonosulfate activation over Mn(III)-rich NiMn-LDH for deep degradation of emerging organic contaminants at high salinity condition: Mechanistic insights and toxicity assessment.
Xia X, Wang L, Cheng Q, et al. · J Colloid Interface Sci 2027
- Combining suspect screening and advanced flow analysis for the investigation of UV-light exposed microplastics: Automatic dynamic bioaccessibility tests of plasticizers and degradation products.
Sixto A, Pons M, Sahragard A, et al. · Talanta 2027
- Target quantification and ion mobility-HRMS suspect screening of BPA and its alternatives in human urine.
De Santo R, Coppola L, Ferri F, et al. · Talanta 2027
- Defect-interface co-regulated sulfur-vacancy-rich MoS2@Fe3O4/Ti3C2Tx MXene S-scheme heterojunction for dual-field-driven peroxydisulfate photoactivation.
Tian Y, Duan X, Yuan S, et al. · J Colloid Interface Sci 2027
- Insight into reactive oxygen species pathway regulation: Boosting FeS2 Fenton catalysis via wet mechanochemically induced dual boron modification involving doping and heterostructure construction.
Wang Q, Shi X, Zhang L, et al. · J Colloid Interface Sci 2027
Also in development for Hemophilia
- STSP-0601Phase 31 trial
Jiangsu BioJeTay Biotechnology Co., Ltd. · Hemophilia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.